Health & Wellness

Atlantic Health System Cancer Care First in World to Begin Clinical Trial of Novel Virus-Based Immunotherapy for Late-Stage Melanoma; First Patient Enrolled

42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg
42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg

Dr. Eric Whitman Leads Study of Experimental Drug That Uses Cold Virus to Disable Cancer Cells in Patients Who Have Not Responded to Other Treatments

Morristown, NJ Atlantic Health System Cancer Care is the first oncology institution in the world to sign on to, and to enroll the first patient in, a multicenter Phase IIa clinical trial of OBP-301 (Telomelysin®), a virus-based immunotherapy for late-stage melanoma that has not responded to other treatments. 

This leading-edge experimental therapy, which is under development by Japanese biotechnology company Oncolys BioPharma, uses the common cold virus to modify a gene that can selectively replicate in, and destroy, cancer cells. The study protocol was approved by the U.S. Food and Drug Administration (FDA) in June.

Sign Up for E-News

The clinical trial is being led locally by Eric D. Whitman, MD, FACS, medical director of Atlantic Health System Cancer Care and director of the Carol G. Simon Cancer Center’s Atlantic Melanoma Center at Morristown Medical Center and Overlook Medical Center.

“This targeted immunotherapy holds great promise for improving survival rates in patients with unresectable and metastatic melanoma,” said Dr. Whitman.  “We are proud to have been chosen as the first site for this leading edge clinical trial, and happy to be able to offer a wide range of the latest established and experimental treatments to our patients.”

Melanoma, the most serious form of skin cancer, affects more than 50,000 people each year. Although the chances of having melanoma increase with age, the number of cases among young adults is rising every year. Melanoma can have serious health consequences and may even be fatal.

The OBP-301 trial is a multicenter, Phase IIa study to evaluate how melanoma tumors respond to injection of this drug in patients with Stage III and Stage IV melanoma -- that is, to determine how much the drug shrinks or destroys tumors after it is injected into them.  The study, which will also look at potential side effects, is “open label,” meaning that all participants in the study will receive OBP-301. 

OBP-301 is a type of virus known as an adenovirus. Adenoviruses are common in nature and when they multiply in normal human cells they may cause infections that result in symptoms like those of the common cold or the flu.  OBP-301 has been genetically changed from the original virus to reproduce in target cancer cells that are emitting a certain signal. As a result of this reproduction, OBP-301 is believed to burst and kill tumor cells.

Study participants will receive multiple injections into their tumors over a period of several weeks.  Blood tests will be done to evaluate the level of virus in patients’ systems, and for immune response monitoring. Dr. Whitman and colleagues will also evaluate how long it takes to get a response and how long responses last, as well as overall survival and progression-free survival rates.

In preclinical studies, Oncolys demonstrated OBP-301’s anti-tumor activity in various types of cancer cells.  A Phase I clinical trial in the U.S. demonstrated the drug’s safety, and showed that it shrank tumors in a majority of study participants, who had a variety of solid tumors.  Additional studies of the drug have been completed, or are underway, in Japan, Korea and Taiwan.

The Atlantic Melanoma Center, a clinical and research center of excellence, is an internationally-recognized program. The center’s multidisciplinary approach-- combining the expertise of board-certified surgeons, medical oncologists, pathologists, radiation oncologists and nurses – treats all forms of melanoma, including those in the skin, mucous membranes and eyes.  Patients receive the latest medical treatments, and when needed, melanoma surgery is also available. 

For more information on the OBP-301 clinical trial or other studies, please call the Atlantic Melanoma Center at 973-971-7111.  

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Millburn/Short Hills

Merry Christmas from TAPinto Millburn-Short Hills

December 24, 2017

MILLBURN, NJ - The staff at TAPinto Millburn-Short Hills wish all our readers who celebrate a Merry Christmas.  

Millburn Police Investigate Theft by Nordstrom Employee

February 14, 2018

Press Release February 13, 2018

 

On February 6, 2018 Millburn Police Officer Royce stopped a 2009 Jaguar XKR as it exited the mall for having no front plate. The investigation led to the arrest of 50 year old Christopher Garibian of Morristown on an outstanding traffic warrant out of Morris Township. Mr. Garibian was placed under arrest, issued summonses, and released after posting ...

AtlantiCast

AtlantiCast Medical Minute: Atlantic Orthopedic Institute’s Scoliosis and Spinal Deformity Center

On this episode of the AtlantiCast Medical Minute, we’ll take you inside the Atlantic Orthopedic Institute’s Scoliosis and Spinal Deformity Center, with the center’s director, Jason Lowenstein, MD.

Video Link: https://www.youtube.com/watch?v=1M7euCp86-c

AtlantiCast Episode 011

Breaking Atlantic Health System news on this week’s AtlantiCast! Plus, find out why Morristown Medical Center is one of the best hospitals in the nation when it comes to recovering from joint surgery, see the newest center for fighting brain cancer and an Atlantic Health System red-carpet premiere!

 

Upcoming Events

Carousel_image_ab8f5d9efb4317e5a445_hiawatha

Sun, February 18, 3:00 PM

Lawton C. Johnson Middle School , Summit

New Jersey Intergenerational Orchestra Free ...

Arts & Entertainment

Carousel_image_5d123ce5c4d1e1aff10d_bd8cb329891587dd07a9_programs_orchestras-header-photo-1024x312

Sun, February 18, 3:00 PM

Lawton C. Johnson Summit Middle School, Summit

Come to NJIO's Winter Concert on Sunday, February ...

Arts & Entertainment

Carousel_image_f26368aa9b02b695afce_3fc10d7c6037ec8915fb_0952ca79b18478625c5395f2431688f1

Mon, February 19, 7:45 PM

Education Center, Millburn

Millburn Board of Education Meeting

Millburn Township Republican County Committee Call for Potential Candidates

February 17, 2018

Registered Republicans interested in serving our community are encouraged to run for the single open Township Committee seat in the 2018 election.  The Millburn Township Republican County Committee invites prospective candidates to arrange an interview by contacting Chairwoman, Mary McNett, at 973-376-3345 or via e-mail at mary.mcnett @gmail.com.

Ms. McNett noted ...

Harry Connick, Jr. to Appear in the World-Premiere Production of "The Sting"

Paper Mill Playhouse (Mark S. Hoebee-Producing Artistic Director, Todd Schmidt-Managing Director), recipient of the 2016 Regional Theatre Tony Award, has announced that Harry Connick, Jr. will star as Henry Gondorff in the world-premiere production of The Sting.  The musical is based on the 1973 film, and will have its world premiere at Paper Mill Playhouse for a limited run from March ...

Millburn Church to Host Renowned Organist Christopher Houlihan

On Sunday, February 18, at 4 pm Christopher Houlihan, hailed as “dazzling” by the Wall Street Journal, will play the renowned Baroque-style Beckerath tracker organ at St. Stephen’s Church, 119 Main Street, Millburn, New Jersey, in a program featuring works by Johann Sebastian Bach, Robert Schumann, Louis Vierne, and Leo Sowerby.   Mr. Houlihan will offer his own ...